Advertisement
NRXP 외환 뉴스
NRx Pharma Achieves Data-lock In Phase 2b/3 Suicidal Treatment Resistant Bipolar Depression Study
Biopharmaceutical company NRx Pharmaceuticals, Inc. (NRXP) announced Monday that it has achieved data-lock in its Phase 2b/3 Suicidal Treatment Resistant Bipolar Depression Study with NRX-101. With data-lock, the complete data set is transferred for independent statistical analysis. The top-line data release is expected in April 2024.
RTTNews
|
497 일 전
NRx Pharmaaeuticals To Receive First $5 Mln Milestone Payment From Partners Alvogen And Lotus Pharma
Biopharmaceutical company NRx Pharmaceuticals, Inc. (NRXP) announced Monday the advance of the first $5 million milestone payment based on the Company's partnership agreement with Alvogen, Inc. and Lotus Pharmaceutical Co. Ltd.
RTTNews
|
553 일 전
NRx Pharma Says FDA Grants Permission To Proceed On IND For NRX-101 To Treat Chronic Pain
Biopharmaceutical company NRx Pharmaceuticals, Inc. (NRXP) announced Monday that FDA has given the company clearance to proceed with human trials to treat Chronic Pain under the Investigational New Drug (IND) application filed with the U.S. Food and Drug Administration (FDA) for the use of NRX-101.
RTTNews
|
687 일 전
